Manufacturer AstraZeneca is again experiencing problems with the supply of corona vaccines to the European Union. In the second quarter, the British-Swedish company will deliver 70 million vaccines instead of the agreed 180 million, European Commission President Ursula von der Leyen reports Wednesday.
The problems surrounding AstraZeneca’s corona vaccine continue to accumulate at a rapid pace. The pharmaceutical company has had to reduce the expected volume of deliveries several times.
In addition, several countries, including the Netherlands, have temporarily stopped administering the AstraZeneca vaccine, because blood clots have developed in vaccinated people in other countries.
According to the European Medicines Agency (EMA), there are no indications to date that there is a link between these complaints and the AstraZeneca vaccine.
Due to the more limited deliveries, tensions between the company and Brussels have risen. Between the lines, the EU accused the pharmaceutical company of favoring other customers.
No evidence that vaccine causes thrombosis
Meanwhile, experts continue to say the AstraZeneca vaccine is safe and there is no evidence that it causes thrombosis or other clotting symptoms in the blood.
Up to Monday, ten reports of thrombosis or embolism following a vaccination with the AstraZeneca corona vaccine have been received in our country. It is not yet known whether there is a causal relationship between the reports and the corona vaccine.
According to outgoing Minister Hugo de Jonge (Public Health), the AstraZeneca vaccine will not be used for two weeks as a precaution.
– .
